Elanco officer awarded options and stock units

Elanco Animal Health officer Ellen de Brabander reported equity compensation changes.

Accepted by SEC EDGAR 03/03/2026 - 07:14 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Elanco Animal Health officer Ellen de Brabander reported equity compensation changes. She received an employee stock option for 51,819 shares and grants of 67,564 and 25,360 shares of common stock, all at a price of $0.00 per share. A separate 46,278-share disposition at $26.40 per share covered tax obligations. The footnotes state that both the restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider de Brabander Ellen

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	51,819	$0.00	$0.00
Grant/Award	Common Stock	67,564	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	46,278	$26.40	$1.22M
Grant/Award	Common Stock	25,360	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 51,819 contracts (Direct); Common Stock — 268,386 shares (Direct)

Holdings Before and After: Employee Stock Option (right to buy), 0 to 51,819 contracts (Direct); Common Stock, 221,740 to 268,386 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
2. F2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Elanco (ELAN) report for Ellen de Brabander?

Elanco reported that officer Ellen de Brabander received an employee stock option for 51,819 shares and two stock grants totaling 92,924 common shares, plus a 46,278-share tax-related disposition at $26.40 per share, all dated March 1, 2026.

Were the Elanco (ELAN) insider transactions open-market buys or sells?

The transactions were equity awards and a tax-related share disposition, not open-market trades. Options and stock were granted at $0.00 per share, while 46,278 shares were delivered at $26.40 per share to satisfy tax or exercise obligations.

How many Elanco (ELAN) stock options were granted to Ellen de Brabander?

Ellen de Brabander was granted an employee stock option covering 51,819 shares. According to the footnotes, these options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, aligning with a multi-year compensation schedule.

What Elanco (ELAN) stock awards did Ellen de Brabander receive?

She received common stock grants of 67,564 shares and 25,360 shares at $0.00 per share. The filing describes these as grant or award acquisitions, indicating equity-based compensation that increases her direct ownership in Elanco common stock.

How do the Elanco (ELAN) equity awards vest for Ellen de Brabander?

The restricted stock units and stock options vest in three equal parts. One-third vests on March 1, 2027, another third on March 1, 2028, and the final portion on March 1, 2029, creating a staggered, three-year vesting timeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Brabander Ellen

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		67,564	A	$0	289,304	D
Common Stock	03/01/2026		F		46,278	D	$26.4	243,026	D
Common Stock	03/01/2026		A		25,360(1)	A	$0	268,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		51,819		(2)	03/01/2036	Common Stock	51,819	$0	51,819	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Remarks:

Executive Vice President, Research, Development and Regulatory Affairs

	/s/ Amy C. Seidel, as Attorney-in-Fact for Ellen de Brabander	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.